

Leukemogenesis by Gross passage A murine leukemia virus: Expression of viruses with recombinant *env* genes in transformed cells

(intrathymic injection/primary thymoma/virus isolation/primary *env* gene product/peptide mapping)

NANCY G. FAMULARI*, CHARLES F. KOEHNE, AND PAUL V. O'DONNELL

Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10021

Communicated by Ludwik Gross, March 29, 1982

ABSTRACT Gross passage A murine leukemia virus (MuLV) derived from extracts of C3Hf/Bi mouse leukemias has been shown to be a virus complex consisting of ecotropic, xenotropic, and recombinant, dualtropic MuLV components. The three virus components were distinguished biochemically by differences in the molecular weights and peptide maps of their primary *env* gene products synthesized in infected cells *in vivo* and *in vitro*. Virus expression was studied in primary leukemias induced in C3Hf/Bi mice by Gross passage A virus extracts and by the individual ecotropic and recombinant MuLV components that were isolated *in vitro*. Our findings suggest that expression of the recombinant MuLV component of the Gross passage A virus complex is necessary and sufficient for the induction of leukemias in C3Hf/Bi mice. In contrast, induction of leukemias by the ecotropic virus component appears to involve generation of a second virus with characteristics of recombinant, dualtropic MuLV.

Considerable recent evidence indicates that genetic recombination between the *env* genes of ecotropic- and xenotropic-related murine leukemia virus (MuLV) is essential for acquisition of viral determinants of leukemogenicity in mice (1-16). Apparently inconsistent with this concept are results with Gross passage A virus, originally derived from extracts of a spontaneous AKR mouse leukemia by serial passage in mice of the low leukemia incidence strain C3Hf/Bi (17). Only ecotropic MuLV has been isolated *in vitro* from Gross passage A extracts of C3Hf/Bi leukemias (2, 18, 19). The cloned Gross ecotropic MuLV (G-MuLV) induces leukemias in C3Hf/Bi mice, although with a longer latent period and lower incidence than the original Gross passage A extracts (19, 20). The difference in biological activity between mouse-passaged virus and the virus isolated and propagated in tissue culture has not been explained. One possibility that we have examined in this study is that the difference in biological activity between *in vivo* and *in vitro* passaged Gross virus is due to loss of a hitherto undetected virus component during isolation procedures *in vitro*. Using a protocol that can detect and distinguish biochemically ecotropic, xenotropic, and recombinant, dualtropic MuLV components existing as virus mixtures (21), we have determined that Gross passage A virus is a mixture consisting predominantly of ecotropic and recombinant MuLV components. The isolated recombinant MuLV alone is leukemogenic. The isolated ecotropic MuLV is leukemogenic also but this is apparently due to its ability to regenerate a recombinant MuLV component *in vivo*.

MATERIALS AND METHODS

Mice. C3Hf/Bi mice were obtained from the Core Breeding Facility of this institute. This strain of mice has been maintained

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact.

by brother-sister mating in our colony from founder stock obtained in 1961 by L. J. Old and E. A. Boyse from L. Gross. All mice used in our experiments were immunized against Sendai virus.

Viruses. Passage 104 of Gross passage A virus was provided generously by Ludwik Gross. Gross passage A virus is defined as a 10% (wt/vol) extract in physiological saline of target tissues (thymus and mesenteric lymph node) of a C3Hf/Bi mouse leukemia (17). Subsequent passages in C3Hf/Bi mice and preparation of cell-free extracts were performed as described by Gross *et al.* (17, 20) with the exception that extracts were filtered through 0.8- μ m Miltex filters (Millipore Corp.) prior to use. Pool 1833B1 of the tissue culture virus (G-MuLV) isolated from Gross passage A virus was obtained from Janet W. Hartley. The tissue culture history of this virus isolate has been described (19). Isolation and characterization of cloned AKR ecotropic, xenotropic, and dualtropic [mink cell focus-inducing (MCF)] MuLV 69E5, 69X9, and 69L1, respectively, have been described (14).

Virus Isolation *in vitro* and Bioassay. Virus recovery *in vitro* was performed by infection of either mouse SC-1 cells or mink CCL64 cells with 0.5 ml of cell-free virus extract according to standard procedures. Infected cells were subcultured at 7-day intervals and assayed for expression of MuLV *gag*-coded p30 antigen at each subculture by indirect immunofluorescence of acetone-fixed cells by using a rabbit antiserum to p30 protein of Rauscher (R)-MuLV (14). All cultures of infected cells used in pulse-labeling experiments were 100% positive for expression of p30 antigens.

Suckling mice (3-5 days of age) were injected intraperitoneally (i.p.) with 0.1 ml of virus inoculum and weaned at approximately 21 days of age. All mothers of virus-injected mice were sacrificed at weaning. Weanling mice were injected by the intrathymic (i.t.) route with 0.15 ml of virus inoculum as described (22). Virus inocula consisted of filtered cell-free extracts of thymomas or supernatants of chronically infected tissue culture cells. Control mice were injected with either phosphate-buffered saline (extracts) or Dulbecco's modified Eagle's minimal essential medium supplemented with 10% heat-inactivated fetal calf serum (culture supernatants).

Radiolabeling and Immunoprecipitation of Virus-Infected Fibroblasts and Primary Leukemia Cells. Petri dishes (100 mm) of confluent virus-infected fibroblasts were pulse-labeled for 15 min with 80 μ Ci of [³H]leucine (New England Nuclear;

Abbreviations: MuLV, murine leukemia virus; G-MuLV, Gross ecotropic MuLV; R-MuLV, Rauscher MuLV; MCF, mink cell focus-inducing; i.p., intraperitoneal(ly); i.t., intrathymic; pr-*env*, primary *env* gene product of ecotropic and dualtropic (MCF) MuLV; GPA-V1, GPA-V2, and GPA-V3, Gross passage A-viruses 1, 2, and 3, respectively.

*To whom reprint requests should be addressed.

1 Ci = 3.7×10^{10} becquerels) per ml of leucine-deficient Eagle's minimal essential medium in a total volume of 2.5 ml. Suspensions of primary leukemias were radiolabeled in a 2-hr pulse at a concentration of 10^6 cells per ml of leucine-deficient minimal essential medium containing 150 μ Ci of [3 H]leucine per ml. Cytoplasmic extracts were prepared and reacted with the appropriate antiserum (21, 23). Goat anti-R-MuLV gp70 serum was obtained from the Office of Program Resources and Logistics, Viral Oncology, National Cancer Institute, and rabbit anti-R-MuLV p15(E) serum was obtained from E. Fleissner of this institute.

NaDodSO₄/Polyacrylamide Gel Electrophoresis. NaDodSO₄/polyacrylamide gel electrophoresis analysis of immunoprecipitates was carried out on 7.5% acrylamide slab gels as described (21) by using modifications of the procedure of Laemmli (24).

Peptide Mapping. Radiolabeled proteins isolated from cell extracts by immunoprecipitation and NaDodSO₄/polyacrylamide gel electrophoresis were subjected to limited proteolysis with *Staphylococcus aureus* V8 protease (Miles) according to Cleveland *et al.* (25). Details of conditions used have been reported (21).

RESULTS

In our analysis of the virus repertoire present in Gross passage A virus extracts, we took advantage of a previous observation that ecotropic and dualtropic (MCF) MuLV can be distinguished by the migration in NaDodSO₄/polyacrylamide gel electrophoresis of their primary *env* gene product (pr-env protein; previously designated PrENV protein) (21). The replication of ecotropic and dualtropic MuLV in the same cell can be detected biochemically by examination of MuLV *env* gene products labeled in a short pulse (see Fig. 1) in spite of the fact that the dualtropic virus component may be masked virologically (refs. 26 and 27; unpublished data). Mouse SC-1 cells coin-




FIG. 1. NaDodSO₄/polyacrylamide gel electrophoresis analysis of pr-env protein of AKR ecotropic and dualtropic viruses. Cytoplasmic extracts were prepared from virus-infected SC-1 cells radiolabeled with [3 H]leucine in a 15-min pulse. Extracts were reacted with rabbit anti-R-MuLV p15(E) serum and resulting precipitates were subjected to electrophoresis in 7.5% acrylamide slab gels. Lane 1, ecotropic MuLV-infected cells; lane 2, cells coinfecting with ecotropic and dualtropic MuLV; lane 3, dualtropic MuLV-infected cells.

fecting with AKR ecotropic virus (69E5) and AKR dualtropic virus (69L1) were pulse-labeled for 15 min with [3 H]leucine, cytoplasmic extracts of these cells were subjected to immunoprecipitation with rabbit anti-R-MuLV p15(E) serum, and immunoprecipitates were analyzed by NaDodSO₄/polyacrylamide gel electrophoresis (Fig. 1, lane 2). Cells infected with either AKR 69E5 or AKR MCF 69L1 viruses also were subjected to the same procedure and the resulting immunoprecipitates were electrophoresed to serve as marker proteins (Fig. 1, lanes 1 and 3, respectively). The ecotropic virus pr-env protein and dualtropic virus pr-env protein are easily distinguishable by migration when isolated from cells infected with either virus alone or from coinfecting cells.

Isolation of Viruses from Gross Passage A Virus Extracts. Virus was recovered *in vitro* from two consecutive Gross passage A extracts (p104 and p105) by infection of either mouse SC-1 cells or mink CCL64 cells. Infected cells were pulse-labeled for 15 min with [3 H]leucine and cytoplasmic extracts were immunoprecipitated with goat anti-R-MuLV gp70 serum or rabbit anti-R-MuLV p15(E) serum. When the resulting immunoprecipitates were analyzed by NaDodSO₄/polyacrylamide gel electrophoresis, two pr-env proteins were identified in infected SC-1 cells (Fig. 2A, lanes 3 and 4). One of the pr-env proteins expressed in infected SC-1 cells comigrated with G-MuLV pr-env proteins (Fig. 2A, lanes 2, 3, and 4) and the other pr-env protein comigrated with MCF 69L1 virus pr-env protein (Fig. 2A, lanes 3, 4, and 5). A single pr-env protein was expressed in infected mink cells and comigrated with that of MCF 69L1 virus (Fig. 2A, lanes 5 and 6). Partial protease digest mapping was used to compare the three pr-env proteins encoded by the recovered viruses with the pr-env proteins encoded by AKR ecotropic virus 69E5, G-MuLV, AKR MCF 69L1 virus, and a xenotropic virus induced by IdUrd from C3Hf/Bi mouse embryo cells (Fig. 2B). We have shown that peptide maps generated with *S. aureus* V8 protease distinguish the pr-env proteins of ecotropic, xenotropic, and dualtropic (MCF) MuLV (28). The pr-env protein expressed in SC-1 cells infected by Gross passage A virus extracts that comigrates with that of G-MuLV is indistinguishable from the pr-env of G-MuLV by this mapping procedure (Fig. 2B, lanes 1 and 2). It should be noted that the map of G-MuLV pr-env protein is distinguishable from that of endogenous AKR ecotropic MuLV 69E5 (Fig. 2B, lane 3). The fast-migrating pr-env protein expressed in SC-1 cells infected by Gross passage A virus extracts generates a map that is similar but not identical with that of MCF 69L1 virus (Fig. 2B, lanes 4 and 5). The pr-env protein encoded by virus recovered from Gross passage A virus extracts in mink cells is indistinguishable from that of C3Hf/Bi endogenous xenotropic MuLV (Fig. 2B, lanes 6 and 7).

Thus, it appears from this analysis that three distinct viral genomes are present in extracts of Gross passage A virus and are recoverable in mouse or mink cells *in vitro*: (i) an ecotropic component that is indistinguishable from G-MuLV isolated in 1965 by J. Hartley but distinguishable from endogenous AKR ecotropic MuLV, (ii) endogenous xenotropic MuLV, and (iii) a virus component that resembles the leukemogenic, *env* gene recombinant virus MCF 69L1 isolated from an AKR thymoma.

Virus Expression in Leukemias Induced by Injection of Gross Passage A Virus Extracts. Leukemias were induced in C3Hf/Bi mice by two routes of injection, the classical route of i.p. injection into suckling mice and by i.t. injection into weanling mice. Suspensions of primary thymoma cells were pulse-labeled for 2 hr *in vitro* with [3 H]leucine and MuLV pr-env proteins were isolated from cytoplasmic extracts by immunoprecipitation with anti-p15(E) serum and NaDodSO₄/polyacrylamide gel electrophoresis. A series of five leukemias in-




FIG. 2. Viruses isolated *in vitro* from Gross passage A virus extracts: characterization by NaDodSO₄/polyacrylamide gel electrophoresis (A) and partial protease digest mapping of the pr-env protein (B). (A) Anti-p15(E) serum was used to isolate pr-env proteins from pulse-labeled cells infected by Gross passage A virus extract p104 or p105. Marker pr-env proteins of ecotropic and dualtropic MuLV were isolated from infected cells with anti-gp70 serum. Immunoprecipitates were analyzed in 7.5% acrylamide gels. Cells in which virus was grown are indicated: lane 1, AKR ecotropic MuLV 69E5; lane 2, G-MuLV; lane 3, Gross passage A virus (p104); lane 4, Gross passage A virus (p105); lane 5, AKR dualtropic (MCF) MuLV 69L1; lane 6, Gross passage A virus (p105). (B) pr-env proteins isolated by the above procedure were subjected to partial digestion with *S. aureus* V8 protease and protein fragments were analyzed in 15% acrylamide slab gels. Lane 1, slow migrating pr-env protein isolated from SC-1 cells infected by Gross passage A virus (p105); lane 2, G-MuLV; lane 3, AKR ecotropic MuLV 69E5; lane 4, fast-migrating pr-env protein isolated from SC-1 cells infected by Gross passage A virus (p105); lane 5, AKR dualtropic (MCF) MuLV 69L1; lane 6, mink cells infected by Gross passage A virus (p105); lane 7, C3Hf/Bi xenotropic MuLV.

duced by i.p. injection all expressed two MuLV pr-env proteins—one comigrating with that of G-MuLV and one comigrating with that of MCF 69L1 virus. Analysis of a representative leukemia is presented in Fig. 3A (lane 2). In addition, infection of SC-1 cells with cell-free extracts of these leukemias resulted in recovery of viruses that expressed both pr-env species (Fig. 3A, lane 3). Peptide mapping was used to compare the pr-env species expressed in the primary leukemias or encoded by viruses transmissible to SC-1 cells with those of G-MuLV and MCF 69L1 virus (Fig. 3A, lanes 5–9). In all instances, the map of the slow-migrating pr-env species was identical to that of G-MuLV and the fast-migrating pr-env species was similar, but not identical, to that of MCF 69L1 virus.

Analysis of five primary leukemias induced by i.t. injection revealed the expression of only one pr-env species that comigrated with that of MCF 69L1 virus. Analysis of a representa-




FIG. 3. Analysis of viruses expressed in primary thymomas induced in C3Hf/Bi mice by injection of Gross passage A virus extracts. Suspensions of primary thymomas and monolayers of SC-1 cells infected by cell-free extracts of these same thymomas were pulse-labeled as described in *Materials and Methods*. Cytoplasmic extracts of these cells were reacted with anti-p15(E) serum and precipitates were analyzed by NaDodSO₄/polyacrylamide gel electrophoresis in 7.5% acrylamide slab gels (A and B, lanes 1–4). pr-env proteins of G-MuLV and MCF 69L1 virus isolated from infected fibroblasts with anti-gp70 serum were included as markers. pr-env proteins isolated by the above procedure were subjected to partial digestion with *S. aureus* V8 protease and protein fragments were analyzed in 15% acrylamide slab gels (A, lanes 5–9; B, lanes 5–7). (A) Suckling mice injected by i.p. route. Lane 1, G-MuLV; lane 2, thymoma cells; lane 3, SC-1 cells infected by thymoma extract; lane 4, MCF 69L1; lane 5, slow-migrating pr-env isolated from thymoma; lane 6, G-MuLV pr-env; lane 7, fast-migrating pr-env isolated from thymoma; lane 8, fast-migrating pr-env isolated from SC-1 cells infected by thymoma extract; lane 9, MCF 69L1 pr-env. (B) Young adult mice injected by i.t. route. Lane 1, G-MuLV; lane 2, thymoma cells; lane 3, SC-1 cells infected by thymoma extract; lane 4, MCF 69L1; lane 5, pr-env isolated from thymoma; lane 6, pr-env isolated from SC-1 cells infected by thymoma extract; lane 7, MCF 69L1 pr-env.

tive leukemia is shown in Fig. 3B (lane 2). In no instance was the expression of G-MuLV detectable in the leukemia cells. Furthermore, infection of SC-1 cells with cell-free extracts of these leukemias resulted in recovery of virus that encoded only the fast-migrating pr-env protein (Fig. 3B, lane 3). Peptide maps of this pr-env protein show that it is indistinguishable from that of the fast-migrating pr-env protein expressed in leukemias induced by i.p. injection of Gross passage A virus into suckling mice. This result indicated that the second virus component present in stocks of Gross passage A virus [subsequently termed Gross passage A-virus 2 (GPA-V2)] was thymotropic and leukemogenic. As a consequence of varying the route of injection of Gross passage A virus into C3Hf/Bi mice, GPA-V2 was sep-

arated from the ecotropic G-MuLV component [subsequently termed Gross passage A-virus 1 (GPA-V1)].

Leukemogenicity of GPA-V1 and GPA-V2 Virus Components Recovered from Gross Passage A Virus Extracts. Leukemias were induced in C3Hf/Bi mice by either GPA-V1 or GPA-V2 viruses that have been propagated in mouse SC-1 cells *in vitro*. Cell suspensions of the primary thymomas were pulse-labeled as described above and MuLV *env* gene products were isolated by immunoprecipitation and NaDodSO₄/polyacrylamide gel electrophoresis. Three leukemias induced by i.p. injection of the ecotropic virus component GPA-V1 into suckling mice were analyzed. A representative leukemia is shown in Fig. 4 (lanes 2 and 3). Two pr-*env* proteins—one comigrating with the pr-*env* protein of the input GPA-V1 virus and one comigrating with the pr-*env* protein of MCF 69L1 virus—were expressed in these thymomas. The pr-*env* protein of MCF 69L1 virus and the fast-migrating pr-*env* protein isolated from the thymoma appear as doublets in Fig. 4. Formation of doublets in NaDodSO₄/polyacrylamide gel electrophoresis is a property of dualtropic virus pr-*env* proteins that we have observed variably in the analysis of AKR virus isolates replicating *in vivo* and *in vitro* (28, 29). The molecular basis of this phenomenon is unknown. Injection of GPA-V1 by the i.t. route resulted in no leukemias to date (357 days postinjection), whereas the average latent period of leukemia induction observed after i.p. injection of GPA-V1 was 183 days. In contrast, leukemias were induced in C3Hf/Bi mice after injection of the dualtropic-like virus component GPA-V2 by either the i.p. or i.t. route with an average latent period of 154 days. One leukemia induced by i.p. injection and five leukemias induced by i.t. injection were analyzed biochemically. Representatives of leukemias induced by both protocols are shown in Fig. 4 (lanes 5 and 6). In all instances, leukemias induced by GPA-V2 virus expressed only a single pr-*env* protein that comigrated with that of the injected GPA-V2 virus and MCF 69L1 virus.

Extracts of leukemias induced by GPA-V1 and GPA-V2 viruses were used to infect SC-1 cells and these cells were ana-

lyzed for expression of MuLV pr-*env* proteins. Viruses encoding both the fast- and slow-migrating pr-*env* proteins were recoverable from leukemias induced by GPA-V1 virus alone (data not shown). Only MuLV encoding the fast-migrating pr-*env* species was recovered from extracts of leukemias induced by the GPA-V2 virus (data not shown).

Our findings suggest that expression of the dualtropic virus component GPA-V2 of the Gross passage A virus complex is necessary and sufficient for the induction of leukemias in C3Hf/Bi mice. In contrast, induction of leukemias by the ecotropic virus component GPA-V1 appears to involve generation of a second virus with characteristics of recombinant dualtropic MuLV.

DISCUSSION

It has been possible to identify three distinct MuLV components in Gross passage A virus extracts by exploiting several characteristics of their *env* gene products. Two viruses designated GPA-V1 and GPA-V2 have been isolated in mouse SC-1 cells and identified by the molecular weight in NaDodSO₄/polyacrylamide gel electrophoresis and peptide maps of their pr-*env* proteins. GPA-V1 appears indistinguishable from the XC⁺, ecotropic virus (G-MuLV) that was isolated in 1965 by J. W. Hartley from Gross passage A virus extracts and which has been analyzed extensively (19, 20, 30, 31). GPA-V2 is an XC⁻, dualtropic virus that appears related to AKR dualtropic (MCF) MuLV by the characteristic molecular weight and peptide map of its pr-*env* protein. Although GPA-V2 was infectious *in vivo* as evidenced by leukemogenicity of culture supernatants of infected SC-1 cells, the virus was poorly infectious *in vitro*. Virus transmission was demonstrated most efficiently by infectious center plating and showed a marked preference in host range for mouse SC-1 cells as opposed to mink cells (unpublished data). Thus, virological properties of GPA-V2 differed considerably from those of AKR dualtropic (MCF) MuLV (9, 14) and of dualtropic MuLV isolated recently by Hamada *et al.* (32) from Gross passage A virus-induced leukemias in NFS mice. The third MuLV component in Gross passage A virus extracts designated Gross passage A-virus 3 (GPA-V3) was isolated in mink cells and was identified as xenotropic on the basis of host range and peptide map of its pr-*env* protein. Virological and serological properties of GPA-V1, GPA-V2, and GPA-V3 MuLV will be detailed in a separate publication.

Primary thymomas induced in C3Hf/Bi mice following i.p. injections of suckling mice with Gross passage A virus extracts have been shown to express the pr-*env* protein of both GPA-V1 and GPA-V2. Expression of the xenotropic MuLV component GPA-V3 was not detected in these cells. However, a low level of expression of this virus would be difficult to identify because its pr-*env* protein comigrates with that of GPA-V2. The frequency of GPA-V3 infectious centers in leukemia cell suspensions is very low relative to GPA-V1 and GPA-V2 infectious centers (unpublished data). Thus, GPA-V3 found in cell-free extracts may represent low level expression of endogenous C3Hf/Bi xenotropic MuLV by transformed cells or thymic stromal cells and be present adventitiously in the extracts.

Previous studies have shown that leukemogenic MuLV isolates induced disease with equal efficiency regardless of whether the route of injection was i.p. in suckling mice or i.t. in young adult mice (9, 14). This was also true for leukemia induction by Gross passage A virus extracts. However, examination of primary thymomas induced after i.t. injection showed that only the pr-*env* protein of GPA-V2 was expressed. Moreover, only GPA-V2 was recovered in SC-1 cells *in vitro* from cell-free extracts of these leukemias. Thus, varying the route of injection of Gross passage A virus resulted in the separation




FIG. 4. Characterization of MuLV expression in primary thymomas induced in C3Hf/Bi mice by injection of tissue culture-derived GPA-V1 and GPA-V2 viruses. Suspensions of primary thymomas were pulse-labeled (see *Materials and Methods*) and cytoplasmic extracts reacted with anti-p15(E) serum except where noted. Immunoprecipitates were analyzed on 7.5% acrylamide slab gels. Marker pr-*env* proteins of G-MuLV and MCF 69L1 MuLV were isolated from infected fibroblasts with anti-gp70 serum. Lane 1, G-MuLV; lane 2, thymoma induced by GPA-V1 virus (anti-gp70 serum); lane 3, thymoma induced by GPA-V1 virus; lane 4, MCF 69L1 MuLV; lane 5, thymoma induced by i.p. injection of GPA-V2 into suckling mice; lane 6, thymoma induced by i.t. injection of GPA-V2 into young adult mice.

of the XC⁻, dualtropic MuLV component GPA-V2 from the XC⁺, ecotropic MuLV component GPA-V1.

Once purified *in vitro*, the isolated GPA-V1 and GPA-V2 MuLV components of the Gross passage A virus complex were tested to assess the role played by each virus in the induction of leukemia as a function of the route of injection. Both GPA-V1 and GPA-V2 were leukemogenic in C3Hf/Bi mice. GPA-V1 induced leukemia with lower incidence and longer latency than Gross passage A extracts as reported previously (19, 20), but only when injected by the i.p. route. i.t. injection of GPA-V1 did not result in leukemia development—a finding which suggests that the target cell for transformation by GPA-V1 is not present in thymus. Primary thymomas induced by i.p. injection of GPA-V1 expressed both the pr-env of GPA-V1 and the pr-env of a virus that appeared to be identical to GPA-V2. Because no GPA-V2 could be demonstrated in the stocks of GPA-V1 (G-MuLV) that were obtained from J. W. Hartley and used in these experiments, we conclude that GPA-V2 was induced *in vivo* as a consequence of infection by GPA-V1 and suggest that previously reported leukemogenicity of the ecotropic MuLV component GPA-V1 is due to its capacity to induce GPA-V2-like virus. Thus, it would appear that the leukemogenicity of certain ecotropic MuLV such as GPA-V1 and also including Friend, Moloney, and Rauscher MuLV (8, 12, 15, 33) and AKR SL viruses (6) may derive from their capacity to induce expression of endogenous viral information with transforming potential. This is a property not shared by other endogenous MuLV like AKR 69E5 which was nonleukemogenic in our studies and those of others (6, 9, 14). Consistent with this hypothesis are preliminary studies that suggest that the virus-inducing capacity of GPA-V1 may not be restricted to the T cell lineage. Expression of a pr-env species similar to that encoded by GPA-V2 appears to be induced in mouse SC-1 cells *in vitro* by infection with GPA-V1 but not by AKR ecotropic MuLV. Results of these studies will be reported elsewhere.

The results of our analysis suggest that expression of GPA-V2 in thymocytes is essential for transformation. All leukemias examined were positive for GPA-V2 gene products. GPA-V2 that was propagated free of GPA-V1 in SC-1 cells induced leukemia with an incidence and latent period comparable to that of Gross passage A virus extracts from which this MuLV component was derived. Leukemia induction was independent of the route of injection, and only GPA-V2 pr-env protein was expressed in resultant leukemias.

On the occasion of the thirtieth anniversary of the publication of the work by Dr. Ludwik Gross on the virus etiology of mouse leukemia, we gratefully acknowledge his important contribution to this research. We thank Drs. J. W. Hartley and L. Gross for their gifts of viruses. We also thank Katherine Hedges, Jamie Harris, Karen English, and Dawn Cieplensky for their technical assistance during the course of this work. This work was supported by Grants CA 16599 and CA 27950 from the National Cancer Institute.

1. Elder, J. H., Gautsch, J. W., Jensen, F. C., Lerner, R. A., Hartley, J. W. & Rowe, W. P. (1977) *Proc. Natl. Acad. Sci. USA* **74**, 4676–4680.
2. Hartley, J. W., Wolford, N. K., Old, L. J. & Rowe, W. P. (1977) *Proc. Natl. Acad. Sci. USA* **74**, 789–792.
3. Chien, Y.-H., Verma, I. M., Shih, T. Y., Scolnick, E. M. & Davidson, N. (1978) *J. Virol.* **28**, 352–360.
4. Devare, S. G., Rapp, U. R., Todaro, G. J. & Stephenson, J. R. (1978) *J. Virol.* **28**, 457–465.
5. Fischinger, P. J., Frankel, A. E., Elder, J. H., Lerner, R. A., Ihle, J. N. & Bolognesi, D. P. (1978) *Virology* **90**, 241–254.
6. Nowinski, R. C. & Hays, E. F. (1978) *J. Virol.* **27**, 13–18.
7. Rommelaere, J., Faller, D. V. & Hopkins, N. (1978) *Proc. Natl. Acad. Sci. USA* **75**, 495–499.
8. Vogt, M. (1979) *Virology* **93**, 226–236.
9. Cloyd, M. W., Hartley, J. W. & Rowe, W. P. (1980) *J. Exp. Med.* **151**, 542–552.
10. Green, N., Hiai, H., Elder, J. H., Schwartz, R. S., Khirroya, R. H., Thomas, C. Y., Tschlis, P. N. & Coffin, J. M. (1980) *J. Exp. Med.* **152**, 249–264.
11. Haas, M. & Patch, V. (1980) *J. Exp. Med.* **151**, 1321–1333.
12. Van Griensven, L. J. & Vogt, M. (1980) *Virology* **101**, 376–388.
13. Chattopadhyay, S. K., Lander, M. R., Gupta, S., Rands, E. & Lowy, D. R. (1981) *Virology* **113**, 465–483.
14. O'Donnell, P. V., Stockert, E., Obata, Y. & Old, L. J. (1981) *Virology* **112**, 548–563.
15. Ruscetti, S., Davis, L., Feild, J. & Oliff, A. (1981) *J. Exp. Med.* **154**, 907–920.
16. Chattopadhyay, S. K., Cloyd, M. W., Linemeyer, D. L., Lander, M. R., Rands, E. & Lowy, D. R. (1982) *Nature (London)* **295**, 25–31.
17. Gross, L. (1957) *Proc. Soc. Exp. Biol. Med.* **94**, 767–771.
18. Lieber, M. M., Sherr, C. J. & Todaro, G. (1974) *Int. J. Cancer* **13**, 587–598.
19. Buchhagen, D. L., Pincus, T., Stutman, O. & Fleissner, E. (1976) *Int. J. Cancer* **18**, 835–842.
20. Gross, L. & Dreyfuss, Y. (1978) *Proc. Natl. Acad. Sci. USA* **75**, 3989–3992.
21. Famulari, N. G. & Jelalian, K. (1979) *J. Virol.* **30**, 720–728.
22. Stockert, E., O'Donnell, P. V., Obata, Y. & Old, L. J. (1980) *Proc. Natl. Acad. Sci. USA* **77**, 3720–3724.
23. Kessler, S. W. (1975) *J. Immunol.* **115**, 1617–1624.
24. Laemmli, U. K. (1970) *J. Virol.* **10**, 751–759.
25. Cleveland, D., Fischer, S. G., Kirschner, M. W. & Laemmli, U. K. (1977) *J. Biol. Chem.* **252**, 1102–1106.
26. Fischinger, P. J., Blevins, C. S. & Dunlop, N. M. (1978) *Science* **201**, 457–459.
27. Haas, M. & Patch, V. (1980) *J. Virol.* **35**, 583–591.
28. Famulari, N. G., Tung, J.-S., O'Donnell, P. V. & Fleissner, E. (1980) *Cold Spring Harbor Symp. Quant. Biol.* **44**, 1281–1287.
29. Famulari, N. & Jelalian-English, K. (1981) *J. Virol.* **40**, 971–976.
30. Buchhagen, D. L., Pedersen, F. S., Crowther, R. L. & Haseltine, W. A. (1980) *Proc. Natl. Acad. Sci. USA* **77**, 4350–4363.
31. Pedersen, F. S., Crowther, R. L., Tenney, D. Y., Reimold, A. M. & Haseltine, W. A. (1981) *Nature (London)* **292**, 167–170.
32. Hamada, K., Yanagihara, K., Kamiya, K., Seyama, T. & Yokoro, K. (1981) *J. Virol.* **38**, 327–335.
33. Oliff, A., Ruscetti, S., Douglass, E. C. & Scolnick, E. (1981) *Blood* **58**, 244–254.